Supply of nirmatrelvir/ritonavir and molnupiravir for patients with COVID-19 in the first eight months since listing on the Australian Pharmaceutical Benefits Scheme: A retrospective observational study-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Supply of nirmatrelvir/ritonavir and molnupiravir for patients with COVID-19 in the first eight months since listing on the Australian Pharmaceutical Benefits Scheme: A retrospective observational study

Published:2024-09 Issue:6 Volume:54 Page:104953
ISSN:2666-9919
Container-title:Infectious Diseases Now
language:en
Short-container-title:Infectious Diseases Now

Author:

Lopez Derrick^ORCID,Pritchard Douglas,Sanfilippo Frank M.^ORCID,Kelty Erin,Page Amy,Etherton-Beer Christopher^ORCID,Almeida Osvaldo P.^ORCID,Preen David B.

Publisher

Elsevier BV

Reference35 articles.

1. World Health Organization. WHO Coronavirus (COVID-19) Dashboard [https://covid19.who.int/] [Accessed 27 Feb 2023].

2. COVID-19 therapeutics for nonhospitalized patients;Gandhi;J Am Med Assoc,2022

3. Australian Government Therapeutics Goods Administration. TGA provisionally approves two oral COVID-19 treatments, molnupiravir (LAGEVRIO) and nirmatrelvir + ritonavir (PAXLOVID) [https://www.tga.gov.au/news/media-releases/tga-provisionally-approves-two-oral-covid-19-treatments-molnupiravir-lagevrio-and-nirmatrelvir-ritonavir-paxlovid] [Accessed 27 Feb 2023].

4. New perspectives on antimicrobial agents: Molnupiravir and nirmatrelvir/ritonavir for treatment of COVID-19;Atmar;Antimicrob Agents Ch,2022

5. Oral nirmatrelvir for high-risk, nonhospitalized adults with COVID-19;Hammond;New Eng J Med,2022

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP